Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Dat
05 Décembre 2023 - 10:15PM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced that it will host an investor call on initial data from
its ongoing frontline expansion cohorts in HR-MDS and TP53m AML and
review data from the poster presentation featured at the 65th ASH
Annual Meeting on Wednesday, December 13, 2023 at 8:00 a.m. ET.
Title: Initial Clinical Trial Data
from Phase 1A/B Dose-Expansion Cohorts in Frontline HR-MDS and
TP53m AML and Review of Dose-Escalation Data from ASH 2023 Annual
Meeting
Date & Time: Wednesday,
December 13, 2023 at 8:00 a.m. ET
Webcast Details:
https://lifescievents.com/event/shattucklabs/
To listen to the live webcast, please visit the
Investor Relations page of the Shattuck Labs website here.
Interested participants are required to register in advance for the
webcast. For those who are unable to attend live, a replay will be
available here.
About Shattuck Labs, Inc. Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, (“ARC®”), platform are designed to
simultaneously inhibit checkpoint molecules and activate
costimulatory molecules with a single therapeutic. The company’s
lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block
the CD47 immune checkpoint and simultaneously agonize the CD40
pathway, is being evaluated in multiple Phase 1 trials. Shattuck
has offices in both Austin, Texas and Durham, North Carolina. For
more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
Investor & Media Contact:Conor
RichardsonVice President of Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Shattuck Labs (NASDAQ:STTK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024